Hypothesis

Oral administration of anxiety-reducing Lactobacillus strains (e.g., L. rhamnosus JB-1, L. plantarum LZU-J-TSL6) increases heart rate variability (HRV) through a vagal-dependent pathway that originates in the enteric nervous system (ENS) via serotonergic signaling from enterochromaffin cells. This HRV increase mediates the observed reduction in anxiety-like behavior, and blocking vagal afferent signaling or 5‑HT₃ receptors will abolish both the HRV shift and the anxiolytic effect.

Mechanistic Rationale

The ENS integrates microbial signals and communicates with the brain chiefly through the vagus nerve [ENS as a central mediator in microbiota-gut-brain communication]. Lactobacillus metabolites (e.g., lactate, tryptophan derivatives) stimulate enterochromaffin cells to release serotonin (5‑HT) [L. rhamnosus JB-1 reduces anxiety via vagal pathways; LZU-J-TSL6 increases hippocampal GABA and BDNF]. Released 5‑HT activates 5‑HT₃ receptors on vagal afferent fibers in the gut wall, increasing afferent firing to the nucleus tractus solitarius (NTS). Enhanced NTS activity boosts parasympathetic outflow, raising HRV, particularly in the high‑frequency (HF) band that reflects respiratory‑linked vagal tone. Improved vagal tone then dampens amygdala‑centric fear circuits, lowering anxiety scores [L. rhamnosus significantly reduces anxiety-like behavior].

This mechanistic chain links a peripheral microbial intervention to a centrally mediated autonomic biomarker (HRV) that has not yet been validated for psychobiotic efficacy [HRV not validated as biomarker for gut-brain interventions].

Predictions

1. Primary: Participants receiving the anxiolytic Lactobacillus formulation will show a significant increase in HF‑HRV (ms²) after 4 weeks compared with placebo.
2. Mediation: The change in HF‑HRV will statistically mediate the relationship between probiotic intake and reduction in anxiety scores (e.g., STAI‑State).
3. Specificity: No change in low‑frequency HRV (LF/HF ratio) or time‑domain measures (RMSSD) will be observed unless the vagal pathway is engaged.
4. Falsification: Pharmacological vagal blockade (e.g., low‑dose glycopyrrolate) or 5‑HT₃ antagonism (ondansetron) administered concurrently with the probiotic will prevent both the HRV increase and the anxiolytic benefit, returning outcomes to placebo levels.
5. ENS dependency: In a subset with vagotomized or ENS‑silenced animal models (via selective intestinal 5‑HT₃ receptor knockout), the probiotic will fail to alter HRV or anxiety, confirming the ENS‑vagal serotonergic axis.

Experimental Design

A double‑blind, randomized, placebo‑controlled crossover trial in 60 healthy adults with mild anxiety (STAI‑State 35‑45).

• Arms: (A) Lactobacillus formulation (10⁹ CFU L. rhamnosus JB-1 + 10⁹ CFU L. plantarum LZU-J-TSL6) daily; (B) matched placebo; each 4‑week period with 2‑week washout.
• Measures: Baseline and weekly HRV (5‑min resting ECG, time and frequency domains), fecal microbiota (16S rRNA), plasma tryptamine/5‑HT, and anxiety (STAI‑State, PANAS).
• Falsification sub‑study: In a separate 20‑participant cohort, repeat the probiotic arm with concurrent ondansetron (4 mg BID) or glycopyrrolate (0.2 mg BID).
• Analysis: Mixed‑effects models for HRV and anxiety; mediation analysis (PROCESS macro) testing HF‑HRV as mediator; interaction terms for drug blockade.

Potential Outcomes and Falsifiability

• Supportive: Significant HF‑HRV rise mediating anxiety reduction, blocked by ondansetron/glycopyrrolate → validates HRV as a mechanistic biomarker and confirms the ENS‑vagal serotonergic route.
• Refutatory: No HRV change despite anxiety improvement, or HRV change unrelated to anxiety, or blockade fails to attenuate either outcome → falsifies the hypothesis, suggesting alternative pathways (e.g., immune, endocrine) or that HRV is merely an epiphenomenon.

This framework directly tests the missing link between psychobiotic action, vagal signaling, and a quantifiable autonomic biomarker, moving the field from correlational observations to causal, mechanistic validation.